SGLT2 inhibitor use was associated with a reduced risk of dementia in older adults with mood and psychotic disorders in a target trial emulation study.An intention-to-treat analysis also showed that SGLT2 inhibitor use correlated with lower rates of psychiatric emergency department visits.People with major depression, bipolar disorder, or schizophrenia have an increased risk of dementia in general, but are underrepresented in dementia prevention research.
Use of SGLT2 inhibitors was linked to lower dementia incidence and fewer related psychiatric outcomes in older adults with mood and psychotic disorders, according to a target trial emulation study.
In an intention-to-treat analysis, patients with major depressive disorder, bipolar disorder, or schizophrenia spectrum disorder who used SGLT2 inhibitors were less likely to develop all-cause dementia (OR 0.61, 95% CI 0.52-0.73) and had fewer psychiatric emergency department visits (OR 0.80, 95% CI 0.66-0.97) compared with similar patients who did not use the drugs, reported Jaime Ramos-Cejudo, PhD, of New York University Grossman School of Medicine in New York City, and co-authors.
In a per-protocol analysis, SGLT2 inhibitor use was associated with lower odds of all-cause dementia (OR 0.54, 95% CI 0.40-0.73) and psychiatric hospitalizations (OR 0.56, 95% CI 0.31-1.00), but not psychiatric emergency department visits (OR 0.74, 95% CI 0.53-1.05), the researchers wrote in JAMA Network Open.
